RESUMEN

A series of very potent derivatives of the 30-amino acid peptide hormone glucagon-like peptide-1 (GLP-1) is described. The compounds were all derivatized with fatty acids in order to protract their action by facilitating binding to serum albumin. GLP-1 had a potency (EC(50)) of 55 pM for the cloned human GLP-1 receptor. Many of the compounds had similar or even higher potencies, despite quite large substituents. All compounds derivatized with fatty acids equal to or longer than 12 carbon atoms were very protracted compared to GLP-1 and thus seem suitable for once daily administration to type 2 diabetic patients. A structure-activity relationship was obtained. GLP-1 could be derivatized with linear fatty acids up to the length of 16 carbon atoms, sometimes longer, almost anywhere in the C-terminal part without considerable loss of potency. Derivatization with two fatty acid substituents led to a considerable loss of potency. A structure-activity relationship on derivatization of specific amino acids generally was obtained. It was found that the longer the fatty acid, the more potency was lost. Simultaneous modification of the N-terminus (in order to obtain better metabolic stability) interfered with fatty acid derivatization and led to loss of potency.

Asunto(s)

Glucagón/farmacología , Glucagón/farmacocinética , Fragmentos de Péptidos/farmacología , Fragmentos de Péptidos/farmacocinética , Péptidos/farmacología , Péptidos/farmacocinética , Precursores de Proteínas/farmacología , Precursores de Proteínas/farmacocinética , Acilación , Secuencia de Aminoácidos , Animales , Línea Celular , Cromatografía Líquida de Alta Presión , Cricetinae , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Ácidos Grasos/farmacología , Glucagón/administración & dosificación , Péptido 1 Similar al Glucagón , Riñón/efectos de los fármacos , Riñón/metabolismo , Lisina/química , Datos de Secuencia Molecular , Fragmentos de Péptidos/administración & dosificación , Péptidos/administración & dosificación , Precursores de Proteínas/administración & dosificación , Espectrofotometría Ultravioleta , Relación Estructura-Actividad , Porcinos

RESUMEN

The hexapeptide ac-RYYRWK-NH2 has been described as a potent partial agonist at the nociceptin (NC)/orphanin FQ receptor which has no affinity for mu-, kappa- or delta-opioid receptors. However, it is not clear whether ac-RYYRWK-NH2 is truly selective for the NC receptor, and ac-RYYRWK-NH2 has therefore been radiolabelled and characterised in receptor-binding experiments. Saturation experiments with [3H]ac-RYYRWK-NH2 binding to rat cortical membranes revealed a single high affinity site for [3H]ac-RYYRWK-NH2 (Kd=0.071 +/- 0.018 nM; Bmax=22+/-2 fmol/mg protein). Uncoupling of the G-proteins resulted in a significant 45% increase in Kd and no change in Bmax. [3H]ac-RYYRWK-NH2 binding to rat cortical membranes or to membranes from baby hamster kidney cells expressing human orphan opioid receptor-like (ORL1) was displaced by NC and ac-RYYRWK-NH2 to the same extent. The following rank order of potency was observed: ac-RYYRWK-NH2 > [Tyr14]NC-OH = NC-OH = NC-NH2 > NC, H-(1-13)-NH2 > NC(1-12)-NH2 >> NC(1-11)-NH2 and, thus, displayed a typical NC receptor pharmacology. Novel cyclic analogues of ac-RYYRWK-NH2 were prepared but these structures were much less active when compared to ac-RYYRWK-NH2. In vitro receptor autoradiography with [3H]ac-RYYRWK-NH2 to rat brain sections revealed high levels of binding in the cerebral cortex, amygdala, hypothalamus and superior colliculus, but low levels in the cerebellum and striatum. Overall, the regional distribution was very similar to that of [3H]NC. Ac-RYYRWK-NH2 seems indeed to be selective for the NC receptor and [3H]ac-RYYRWK-NH2 is a novel radioligand which may be useful for further exploring the pharmacology and receptor-ligand interaction of the NC receptor.

Asunto(s)

Oligopéptidos/metabolismo , Receptores Opioides/metabolismo , Amígdala del Cerebelo/metabolismo , Animales , Autorradiografía , Sitios de Unión , Unión Competitiva , Membrana Celular/metabolismo , Corteza Cerebral/metabolismo , Cricetinae , Femenino , Humanos , Hipotálamo/metabolismo , Cinética , Oligopéptidos/farmacología , Péptidos Opioides/metabolismo , Péptidos Opioides/farmacología , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Receptores Opioides/agonistas , Especificidad por Sustrato , Tritio , Receptor de Nociceptina

RESUMEN

The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1. In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6 (ECs) = 1.3+/-0.4nmol/l and Emax = 85+/-5% vs 2.2+/-0.3nmol/l and 100%). A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor. In pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to GHRP-6 (ED50 = 80+/-42nmol/kg and Emax = 1545+/-250ng GH/ml vs 115+/-36nmol/kg and 1167+/-120ng GH/ml). In conscious swine, ipamorelin released GH with an ED50 = 2.3+/-0.03 nmol/kg and an Emax = 65+/-0.2 ng GH/ml plasma. Again, this was very similar to GHRP-6 (ED50 = 3.9+/-1.4 nmol/kg and Emax = 74+/-7ng GH/ml plasma). GHRP-2 displayed higher potency but lower efficacy (ED50 = 0.6 nmol/kg and Emax = 56+/-6 ng GH/ml plasma). The specificity for GH release was studied in swine. None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Very surprisingly, ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release. In conclusion, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development.

Asunto(s)

Hormona del Crecimiento/metabolismo , Hormonas/farmacología , Oligopéptidos/farmacología , Hormona Adrenocorticotrópica/sangre , Anestesia , Animales , Área Bajo la Curva , Gonadotropinas/sangre , Hormona del Crecimiento/sangre , Hormona Liberadora de Hormona del Crecimiento/sangre , Hormonas/química , Hidrocortisona/sangre , Masculino , Conformación Molecular , Oligopéptidos/química , Hipófisis/citología , Hipófisis/efectos de los fármacos , Hipófisis/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Somatostatina/efectos de los fármacos , Estimulación Química , Relación Estructura-Actividad , Porcinos

RESUMEN

A new series of GH secretagogues derived from ipamorelin is described. In an attempt to obtain oral bioavailability, by reducing the size and the number of potential hydrogen-bonding sites of the compounds, a strategy using the peptidomimetic fragment 3-(aminomethyl)benzoic acid and sequential backbone N-methylations was applied. Several compounds from this series release GH with high in vitro potency and efficacy in a rat pituitary cell assay and high in vivo potency and efficacy in anesthetized rats. The tetrapeptide NNC 26-0235 (3-(aminomethyl)benzoyl-D-2Nal-N-Me-D-Phe-Lys-NH2) shows, following iv administration, comparable in vivo potency to ipamorelin, GHRP-2, and GHRP-6 with an ED50 in swine at 2 nmol/kg. NNC 26-0235 demonstrated a 10% oral bioavailability in dogs, and NNC 26-0235 and ipamorelin were able to increase basal GH level by more than 10-fold after oral administration of a dose of 1.8 and 2.7 mg/kg, respectively. The tripeptide NNC 26-0323 (3-(aminomethyl)benzoic acid-N-Me-D-2Nal-N-Me-D-Phe-ol) which showed moderate in vitro potency but lacked in vivo potency demonstrated a 20% oral bioavailability in rats.

Asunto(s)

Hormona del Crecimiento/metabolismo , Hormonas/síntesis química , Oligopéptidos/síntesis química , Administración Oral , Animales , Disponibilidad Biológica , Perros , Femenino , Hormonas/química , Hormonas/farmacocinética , Hormonas/farmacología , Técnicas In Vitro , Inyecciones Intravenosas , Espectroscopía de Resonancia Magnética , Masculino , Imitación Molecular , Oligopéptidos/química , Oligopéptidos/farmacocinética , Oligopéptidos/farmacología , Hipófisis/citología , Hipófisis/efectos de los fármacos , Hipófisis/metabolismo , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Porcinos

RESUMEN

A novel class of growth hormone-releasing compounds with a molecular weight in the range from 500 to 650 has been discovered. The aim of this study was to obtain growth hormone secretagogues with oral bioavailability. By a rational approach we were able to reduce the size of the lead compound ipamorelin (4) and simultaneously to reduce hydrogen-bonding potential by incorporation of backbone isosters while retaining in vivo potency in swine. A rat pituitary assay was used for screening of all compounds and to evaluate which compounds should be tested further for in vivo potency in swine and oral bioavailability, fpo, in dogs. Most of the tested compounds had fpo in the range of 10-55%. In vivo potency in swine after iv dosing is reported, and ED50 was found to be 30 nmol/kg of body weight for the most potent compound.

Asunto(s)

Hormona del Crecimiento/metabolismo , Hormonas/síntesis química , Oligopéptidos/síntesis química , Administración Oral , Animales , Disponibilidad Biológica , Perros , Evaluación Preclínica de Medicamentos , Femenino , Hormonas/química , Hormonas/farmacocinética , Hormonas/farmacología , Inyecciones Intravenosas , Espectroscopía de Resonancia Magnética , Masculino , Modelos Moleculares , Imitación Molecular , Oligopéptidos/química , Oligopéptidos/farmacocinética , Oligopéptidos/farmacología , Hipófisis/citología , Hipófisis/efectos de los fármacos , Hipófisis/metabolismo , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Porcinos

RESUMEN

1. The pharmacokinetics of three new peptidyl growth hormone secretagogues, ipamorelin (NNC 26-0161), NNC 26-0194 and NNC 26-0235, were compared with two well-known hexapeptides, GHRP-2 and GHRP-6, in the male rat following different routes of administration. 2. Following i.v. bolus injection, plasma concentrations of the peptides declined biexponentially. Ipamorelin differed markedly from the other peptides investigated, demonstrating a systemic plasma clearance 5-fold lower than that of GHRP-6. Ipamorelin was mainly excreted in the urine, whereas GHRP-6 was predominantly excreted in the bile. NNC 26-0194 and NNC 26-0235 also showed high biliary excretions. Ipamorelin and the two NNC peptides were moderately resistant towards metabolism as 60-80% of the administered dose could be recovered from bile and urine as intact peptide. 3. After intranasal application, the bioavailability of ipamorelin was estimated at approximately 20%. Higher bioavailabilities of approximately 50% were determined for NNC 26-0235, NNC 26-0194 and GHRP-2, whereas the nasal absorption of GHRP-6 was somewhat lower. Thus, the peptides could be easily transported across the nasal epithelium suggesting that the nasal route seems promising for systemic delivery of this family of peptidyl growth hormone secretagogues.

Asunto(s)

Líquidos Corporales/química , Hormona Liberadora de Hormona del Crecimiento/farmacocinética , Hormonas/farmacocinética , Mucosa Nasal/metabolismo , Oligopéptidos/farmacocinética , Absorción , Administración Intranasal , Animales , Área Bajo la Curva , Bilis/química , Disponibilidad Biológica , Cromatografía Líquida de Alta Presión , Hormona Liberadora de Hormona del Crecimiento/administración & dosificación , Hormona Liberadora de Hormona del Crecimiento/química , Semivida , Hormonas/administración & dosificación , Hormonas/química , Inyecciones Intravenosas , Masculino , Oligopéptidos/administración & dosificación , Oligopéptidos/química , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Orina/química

RESUMEN

A series of pseudopeptide analogues of the C-terminal hexapeptide of neurotensin (NT8-13), namely [Tyr11 psi[COCH2]Phe12]-, [Ile12 psi[COCH2]Phe13]-, and [Tyr11 psi[CH(CN)NH]Ile12]NT8-13 with different stereochemistries, has been synthesized and evaluated for its potency in displacing labeled NT from rat cortex membranes. Ketomethylene pseudohexapeptides were prepared from the corresponding Boc-protected ketomethylene dipeptide derivatives, previously formed, using different solid phase synthesis (SPS) conditions, while (cyanomethylene)amino analogues were directly prepared by SPS using Fmoc strategy. H-Arg-Arg-Pro-Tyr psi[COCH2]-Phe-Leu-OH was nearly as potent as NT8-13 and [Phe12]NT8-13 in binding to the receptor. Comparison of the affinities for the pseudohexapeptides, here reported, with those of the psi-[CH2NH] analogues indicates the importance of the CO group in the amide or surrogate linkage at 11-12 and 12-13 positions in the receptor binding process.

Asunto(s)

Acetonitrilos/síntesis química , Acetonitrilos/farmacología , Neurotensina/análogos & derivados , Oligopéptidos/síntesis química , Oligopéptidos/farmacología , Fragmentos de Péptidos/síntesis química , Fragmentos de Péptidos/farmacología , Acetonitrilos/metabolismo , Secuencia de Aminoácidos , Animales , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Cetonas/síntesis química , Cetonas/metabolismo , Cetonas/farmacología , Datos de Secuencia Molecular , Neurotensina/síntesis química , Neurotensina/metabolismo , Neurotensina/farmacología , Oligopéptidos/metabolismo , Fragmentos de Péptidos/metabolismo , Ratas

RESUMEN

To evaluate more thoroughly the importance of main-chain structure and flexibility in ligand interactions with the insulin receptor, we undertook to synthesize analogues with reduced peptide bonds in the COOH-terminal B chain domain of the hormone (a stable, but adjustable beta-strand region). By use of solid-phase, solution-phase and semisynthetic methods, analogues were prepared in which ArgB22 of des-octapeptide(B23-B30)-insulin was extended by the sequences Gly-Phe-psi (CH2-NH)-Phe-NH2, Gly-Gly-psi(CH2-NH)-Phe-Phe-NH2, Gly-Phe-psi (CH2-NH)-Phe-Phe-Thr-Pro-Ala-Thr-OH, and Gly-Phe-Phe-psi (CH2-NH)-Phe-Thr-Pro-Ala-Thr-OH, and were studied with respect to their abilities both to interact with the hepatocyte insulin receptor and to form soluble anion-stabilized hexamers in the presence of Co2+ and phenol. Additional analogues of des-pentapeptide(B26-B30)-insulin were also examined. Overall, our results show that, whereas all analogues retain considerable ability to form organized metal ion-coordinated complexes in solution, the reduction of peptide bonds both proximal and distal to the critical side chain of PheB25 results in analogues with severely diminished receptor binding potency. We conclude that the peptide carbonyls from both PheB24 and PheB25 are important for insulin-receptor interactions and that the structural organization of the region when insulin is bound to its receptor differs from that occurring during simple monomer-monomer and higher-order interactions of the hormone.

Asunto(s)

Insulina/análogos & derivados , Receptor de Insulina/metabolismo , Secuencia de Aminoácidos , Animales , Relación Dosis-Respuesta a Droga , Hígado/metabolismo , Modelos Químicos , Datos de Secuencia Molecular , Conformación Proteica , Relación Estructura-Actividad

Asunto(s)

Endotelinas/fisiología , Receptores de Endotelina/metabolismo , Animales , Aorta Torácica , Relación Dosis-Respuesta a Droga , Endotelinas/farmacología , Fundus Gástrico/efectos de los fármacos , Contracción Muscular , Músculo Liso Vascular/metabolismo , Músculo Liso Vascular/fisiología , Péptidos , Conejos , Ratas , Relación Estructura-Actividad

RESUMEN

ANP-270 is a 26 amino acid analogue of naturally occurring atrial natriuretic factor (ANF) which it was anticipated would be of value for the treatment of congestive heart failure and acute renal failure. Two sensitive assays--a radioimmunoassay (RIA) and a sandwich enzyme linked immunosorbent assay (ELISA)--were developed and validated for use in clinical investigations. The RIA utilized a single C terminal monoclonal antibody whereas two monoclonal antibodies directed against different epitopes were used for the ELISA. The two assays were comparable with respect to sensitivity and precision, but assay results obtained on samples from normal volunteers dosed intravenously with ANP-270 differed widely. Thus, in one volunteer the elimination half-life was estimated to be 123 min using RIA results but 6 min using the ELISA results. By reversed phase liquid chromatographic fractionation of plasma extracts followed by RIA and ELISA, these discrepancies were shown to be due to fragments of ANP-270 cross-reacting in the RIA but not in the ELISA. Consequently, the sandwich ELISA was the method of choice for estimating this compound in plasma.

Asunto(s)

Factor Natriurético Atrial/sangre , Ensayo de Inmunoadsorción Enzimática/métodos , Fragmentos de Péptidos/sangre , Radioinmunoensayo/métodos , Secuencia de Aminoácidos , Anticuerpos Monoclonales , Factor Natriurético Atrial/genética , Cromatografía Líquida de Alta Presión , Reacciones Cruzadas , Semivida , Humanos , Datos de Secuencia Molecular , Fragmentos de Péptidos/genética , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Factores de Tiempo

RESUMEN

An extensive structure-activity study of synthetic analogues of the C3a anaphylatoxin was conducted. Our goal was to map C3a-C3a receptor interactions by designing synthetic analogue molecules having maximal biologic potency. Nonspecific binding of the polycationic C3a to polyanionic molecules on cellular surfaces often obscures specific binding to the receptor. Less cationic synthetic C3a analogues would be useful tools in identifying and characterizing the various cell types having C3a receptors. These factors should also be useful as pharmacologic probes for mechanism studies, as high-affinity ligands for target cell identification, and for receptor isolation. Attachment of amino-terminal hydrophobic groups such as Fmoc to C3a analogues [as orginally introduced by Gerardy-Schahn et al. (1988) Biochem. J. 255, 209] markedly enhanced the potency of synthetic C3a peptides. The enhancement effect on potency from introducing hydrophobic groups to C3a analogues was interpreted as possibly being nonspecific. Our systematic search for an optimal peptide length, composition, and N-terminal hydrophobic unit resulted in several superpotent C3a analogues having 200-1500% the potency of natural C3a. One particularly potent C3a peptide was designed by incorporating two tryptophanyl residues at the N-terminal end of a 15-residue C3a analogue. The superpotent peptide W-W-G-K-K-Y-R-A-S-K-L-G-L-A-R has several residues differing (underlined) from the sequence corresponding to positions 63-77 in human C3a, a region that contains the essential functional site of the molecule. This 15-residue model peptide exhibited the greatest biological potency of all peptides tested, being 12-15 times more active than natural C3a. Since an optimal distance was found to exist between the N-terminal hydrophobic unit (W-W) and the C-terminal primary binding site (LGLAR), we concluded that the hydrophobic unit interacts specifically with a secondary binding site on the C3a receptor. The presence of both a primary (effector) and secondary (hydrophobic) binding site on these linear synthetic ligands, which can interact cooperatively with the C3a receptor, presumably accounts for the high relative potency of the analogues. Our design of superpotent analogues of C3a demonstrates the feasibility for constructing small synthetic peptides to mimic natural biologic factors that depend on secondary or tertiary structure for their activity. These synthetic peptide studies demonstrate that a linear array of amino acids (e.g., W-W) can successfully substitute for a conformation-dependent binding site on a bioactive factor.

Asunto(s)

Anafilatoxinas/química , Receptores de Complemento/química , Secuencia de Aminoácidos , Anafilatoxinas/síntesis química , Animales , Sitios de Unión , Diseño de Fármacos , Cobayas , Ligandos , Datos de Secuencia Molecular , Conformación Proteica , Solubilidad , Relación Estructura-Actividad

Asunto(s)

Diseño de Fármacos , Proteínas/química , Secuencia de Aminoácidos , Complemento C3a/química , Humanos , Datos de Secuencia Molecular , Péptidos/síntesis química , Péptidos/química

RESUMEN

Neuropeptide Y (NPY) belongs to the pancreatic polypeptide fold (PP-fold) family of regulatory peptides. Analysis of circular dicroic spectra of NPY showed that it has a high degree of secondary structure in aqueous solution which is in agreement with the globular, folded crystal structure of PP. Using three different approaches with synthetic peptides, we have probed the importance of the PP-fold structure in the interaction of NPY with two types of binding sites, Y1 and Y2 receptors. First, stepwise construction of the NPY molecule from the C-terminal amidated end, showed that although C-terminal fragments encompassing most of the long alpha-helix reacted reasonably well with the Y2 receptor, both Y1 and Y2 receptors required the presence of both ends of the PP-fold for full activity. Second, perturbation of the PP-fold by substitution with a helix-breaking proline residue, resulted in the loss of recognition of the N-terminal segment of the molecule by both types of receptors. Finally, a hybrid analog was constructed in which the essential, but by itself inactive, C-terminal segment of NPY was joined with the PP-fold motif of PP. This segment of PP is only 43% homologous to the similar motif in NPY, and most of the common residues cluster in the hydrophobic core of the fold. Nevertheless, the hybrid analog reacted with almost full potency on the Y2 receptors. It is concluded that the antiparallel PP-fold is of structural importance for the receptor binding of NPY, and that its main function is to present the combined C- and N-terminal segments of the molecule to the receptors.

Asunto(s)

Neuropéptido Y/metabolismo , Polipéptido Pancreático/metabolismo , Receptores de Neurotransmisores/metabolismo , Secuencia de Aminoácidos , Animales , Sitios de Unión , Línea Celular , Dicroismo Circular , Hipocampo/metabolismo , Humanos , Modelos Moleculares , Datos de Secuencia Molecular , Neuropéptido Y/síntesis química , Neuropéptido Y/genética , Polipéptido Pancreático/genética , Conformación Proteica , Receptores de Neuropéptido Y , Homología de Secuencia de Ácido Nucleico , Porcinos , Membranas Sinápticas/metabolismo

RESUMEN

A series of glucagon analogues, des-(1-4)-glucagon, des-(5-9)-glucagon, des-(10-15)-glucagon, des-(16-21)-glucagon, des-(22-26)-glucagon and des-(27-29)-glucagon, were prepared by condensation of synthetic fragments and characterized biologically and immunologically. Fully synthetic glucagon was also characterized. The potencies with regard to glucagon receptor binding in purified rat liver plasma membranes were, in decreasing order: synthetic glucagon 108%, des-(1-4)-glucagon 5.7%, des-(27-29)-glucagon 0.92%, des-(5-9)-glucagon 0.47%, des-(10-15)-glucagon 0.0028%, des-(16-21)-glucagon 0.0017% and des-(22-26)-glucagon 0.00060% relative to that of natural porcine glucagon. Des-(27-29)-glucagon was the only analogue that activated the adenylate cyclase in rat liver plasma membranes or stimulated the lipolysis in isolated free fat cells from rat epididymal fat pad. The potencies were 0.16% and 0.20% of that of glucagon, respectively. Des-(1-4)-glucagon was a glucagon antagonist in the adenylate cyclase assay. The immunoreactivities of the glucagon analogues were determined with two commonly used anti-glucagon sera, K 5563 and K 4023, directed towards the C-terminus and some segment in the sequence 2-23, respectively. In the K 5563 assay, des-(27-29)-glucagon and des-(22-26)-glucagon had potencies of 0.0009% and less than 0.09% of that of glucagon, respectively. The remaining analogues had potencies varying from 45% to 141% of that of glucagon. In the K 4023 assay, the analogues showed a non-linear dilution effect. The combined results indicate a partition within the glucagon molecule with regard to receptor binding and adenylate cyclase activation. The region 10-26 appears to be the most important for receptor binding, whereas 1-4 is essential for adenylate cyclase activation. The C-terminal segment 27-29 is important for the maintenance of full receptor binding but non-essential for adenylate cyclase activation.

Asunto(s)

Adenilil Ciclasas/metabolismo , Glucagón/análogos & derivados , Glucagón/farmacología , Movilización Lipídica/efectos de los fármacos , Tejido Adiposo/efectos de los fármacos , Tejido Adiposo/metabolismo , Secuencia de Aminoácidos , Animales , Bioensayo , Membrana Celular/enzimología , Fenómenos Químicos , Química , Relación Dosis-Respuesta a Droga , Glucagón/metabolismo , Hígado/enzimología , Masculino , Ratas , Receptores de Superficie Celular/metabolismo , Receptores de Glucagón , Porcinos

RESUMEN

During acidolysis by TFA of the t-butyl protecting group from Z-Tyr(But) or from Ser (But) in the presence of tyrosine, C-t-butylation occurred in the aromatic nucleus in Z-Tyr or tyrosine, respectively, to an extent of 0.5-1.0%. CF3COOBut formed during the acidolysis slowly C-t-butylates tyrosine. Tyr(3'But) is formed. The synthesis of Tyr (3'But) . HCl is described.

Asunto(s)

Tirosina/análogos & derivados , Fenómenos Químicos , Química , Análisis Espectral , Tirosina/síntesis química

RESUMEN

The trifluoroacetic acid-mediated removal of t-butyl groups in protected amino acids leads to the formation of t-butyl trifluoroacetate. This t-butyl ester alkylates in trifluoroacetic acid methionine and tryptophan. The t-butyl trifluoroacetate ester can be destroyed by scavengers commonly employed for t-butyl cations, and the reaction rates of the scavengers with the ester are used in the evaluation of scavengers. Scavengers of sulphide structure react with t-butyl trifluoroacetate to form sulphonium compounds, which possess alkylating properties. In the presence of a scavenger during acidolysis, the trifluoroacetic acid and the scavenger will compete in reacting with the t-butyl cations. Kinetic studies show comparable reaction rates with thiophenol as scavenger. The usefulness of adding scavengers to trifluoroacetic acid in deblocking reactions is due to the removal of t-butyl trifluoroacetate in addition to the removal of t-butyl cations. Isobutene reacts with trifluoroacetic acid and yields t-butyl trifluoroacetate. The reaction reaches an equilibrium displaced in favour of the ester at room temperature. Hence no isobutene can be expected to escape during a deblocking reaction in trifluoroacetic acid.

Asunto(s)

Fluoroacetatos , Metionina , Péptidos , Ácido Trifluoroacético , Triptófano , Alquilación , Fenómenos Químicos , Química , Fluoroacetatos/análogos & derivados , Compuestos de Sulfonio , Tirosina